Subcutaneous Immunoglobulin Market

The Subcutaneous Immunoglobulin (SCIg) market comprises therapies administered under the skin to deliver antibodies for patients with immunodeficiency disorders. The primary customers are individuals requiring long-term immunotherapy, with a notable trend toward treatment in homecare settings rather than clinics. Key growth drivers include the increasing patient demand for the convenience and autonomy of home-based treatments, coupled with continuous technological innovation in user-friendly delivery devices like portable pumps and pre-filled syringes.